Skip to content

Epidemiology and global burden

TL;DR — Retinoblastoma is rare in population terms but represents about 8,000 childhood diagnoses annually. Age, laterality and heritability are linked: bilateral disease presents earlier and usually signals a germline RB1 alteration, whereas many unilateral tumours are purely somatic. The dominant epidemiological fact is not small geographic variation in incidence but a 42.2-percentage-point gap in three-year survival between high- and low-income countries. Income-stratified denominators, stage and treatment abandonment must accompany every outcome estimate.

Decision-relevant evidence

  • The 2015 primer estimated approximately 8,000 cases each year worldwide and put survival above 95% in high-income countries against below 30% globally (Dimaras 2015, PMID 27189421).

  • The global cohort captured 4,064 children—estimated as about half of 2017 incident cases—from 260 centres in 149 countries, and reported median diagnostic age 23.2 months (IQR 11.0–36.5) (PMID 35839812).

  • cT4 disease occurred in 0.8% (5/636) of high-income, 5.4% (55/1,027) of upper-middle-income, 19.7% (342/1,738) of lower-middle-income and 42.9% (196/457) of low-income participants (PMID 35839812).

  • Low-income residence carried adjusted mortality HR 16.67 (95% CI 4.76–50.00), cT4 versus cT1 carried HR 8.98 (4.44–18.18), and age at diagnosis added HR 1.38 per year (1.23–1.56) up to three years (PMID 35839812).

  • European population-based data give the high-resource comparator: across 81 registries in 31 countries and 3,262 children diagnosed 2000–2013, incidence was 4.0 per million children aged 0–14 (95% CI 3.9–4.1) with no time trend, and five-year survival was 97.8% (95.5–98.9) — but under 80% in Estonia and Bulgaria and 100% in several countries, so "European" conceals a real internal gradient (Virgili 2024, PMID 39388193; commentary Chévez-Barrios 2024, PMID 39388174).

  • The same European cohort recorded 25 subsequent malignant neoplasms over up to 14 years of follow-up, SIR 8.2 overall, 5 for haematological tumours and 29 for bone and soft-tissue sarcomas — early-onset excess risk visible within a childhood-length follow-up window (PMID 39388193).

  • National registry incidence is not uniform and is partly an ascertainment artefact. Argentina's national paediatric registry reported 5.0 per million children 0–14 (95% CI 3.5–6.4) from 438 patients (Moreno 2014, PMID 24729462); Brazilian population-based registries gave 2.23 per million world-standardised for ages 0–14 across 675 patients, with 13% of diagnoses made only on death certificate and 18% not informed — under-ascertainment the authors call out explicitly (Barbosa 2022, PMID 36507141); and an Ethiopian four-hospital chart review found 221 patients over four years, an incidence of 1 per 52,156 live births that the authors state is likely an underestimate given the absence of a national registry (Sherief 2023, PMID 37221479).

  • Where the incident cases actually are matters more than the global average: 43% of the 2013 estimated global burden (3,452 of 8,099 children) lived in six Asia-Pacific countries — India 1,486, China 1,103, Indonesia 277, Pakistan 260, Bangladesh 184 and the Philippines 142 (Jain 2019, PMID 30385881). India's own consensus estimate is about 1,500 cases annually (Singh 2024, PMID 38492167).

  • Socio-economic position operates within countries, not only between them: in Argentina, median age at diagnosis was later in lower human-development provinces (35 versus 24 months unilateral, P = 0.003; 11.5 versus 9 months bilateral, P = 0.027) and three-year survival was 0.93 versus 0.77 (P < 0.0001), with treatment at a tertiary institution independently associated with better survival (P = 0.0015) (PMID 24729462).

  • Heritable disease is roughly 45% of cases, of which about 80% are bilateral — the figure that determines how much of the incident population needs lifelong surveillance rather than episodic care (AlAli 2018, PMID 29737052).

  • In an Indian prospective multicentre cohort of 1,120 children, mean symptom-to-treatment lag was 4.2 months (range 0.5–61.6); parental, diagnostic and treatment components contributed 44%, 26% and 31%, and 25.2% already had extraocular or metastatic disease at diagnosis (Das 2025, PMID 40719713).

  • A resource-limited extraocular cohort reported abandonment in 38.5% of IRSS stage III and 46.6% of stage IV cases; projected overall survival for stage III was 87.5%, 55.6% and 39.7% at one, two and three years, and every stage IV patient died at a median follow-up of three months (Pant 2017, PMID 29337595).

  • Comparing incidence figures across these sources is a methodological trap: they use different denominators (per million children 0–14, per million 0–19, per live birth), different age ceilings and different completeness, which is why they are reported side by side here and never pooled (PMIDs: 39388193, 36507141, 37221479, 24729462).

Clinical and research frame

Domain Operational meaning Evidence boundary
Incidence Population registry Avoid hospital-series denominator
Stage cTNMH/IRSS at diagnosis Report extraocular fraction
Survival Time-to-event with CI Stratify by national income and stage
Abandonment Competing outcome Do not recode as biological failure
Vision Eye-level endpoint Keep separate from child survival

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
27189421 2015 Retinoblastoma. Topic-resolved source (Dimaras 2015, PMID 27189421)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
40719713 2025 Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Topic-resolved source (Das 2025, PMID 40719713)
29337595 2017 Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. Topic-resolved source (Pant 2017, PMID 29337595)
37667345 2023 Retinoblastoma: present scenario and future challenges. Topic-resolved source (Byroju 2023, PMID 37667345)
372907 1979 Retinoblastoma. Topic-resolved source (Bishop 1979, PMID 372907)
16934146 2006 Retinoblastoma. Topic-resolved source (Aerts 2006, PMID 16934146)
16572402 2007 Trilateral retinoblastoma. Topic-resolved source (Antoneli 2007, PMID 16572402)
9333268 1997 Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. Topic-resolved source (Wong 1997, PMID 9333268)
38718232 2024 Increased Incidence of Retinoblastoma in Wisconsin: Coincidence or Public Health Concern? Topic-resolved source (Damodharan 2024, PMID 38718232)
29915458 2018 Understanding retinoblastoma: epidemiology and genetics. Topic-resolved source (Fabian 2018, PMID 29915458)
36408154 2022 Retinoblastoma: Review and new insights. Topic-resolved source (Cruz-Gálvez 2022, PMID 36408154)
29737052 2018 Retinoblastoma for Pediatric Ophthalmologists. Topic-resolved source (AlAli 2018, PMID 29737052)
25473349 2014 Retinoblastoma: An overview. Topic-resolved source (Pandey 2014, PMID 25473349)
33818883 2021 Rare tumors: Retinoblastoma, nasopharyngeal cancer, and adrenocorticoid tumors. Topic-resolved source (Patel 2021, PMID 33818883)
21546735 2011 Orbital retinoblastoma: where do we go from here? Topic-resolved source (Ali 2011, PMID 21546735)
39388193 2024 Survival and Health Care Burden of Children With Retinoblastoma in Europe. Topic-resolved source (Virgili 2024, PMID 39388193)
36507141 2022 Incidence of retinoblastoma in children and adolescents in Brazil: A population-based study. Topic-resolved source (Barbosa 2022, PMID 36507141)
38492167 2024 Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Singh 2024, PMID 38492167)
26679524 2016 [Retinoblastoma update]. Topic-resolved source (Aerts 2016, PMID 26679524)
28019092 2017 Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. Topic-resolved source (Friedman 2017, PMID 28019092)
39388174 2024 Incidence and Survival Rates in European Children With Retinoblastoma. Topic-resolved source (Chévez-Barrios 2024, PMID 39388174)
37221479 2023 Incidence and geographic distribution of retinoblastoma in Ethiopia. Topic-resolved source (Sherief 2023, PMID 37221479)
34042282 2022 Retinoblastoma: from discovery to clinical management. Topic-resolved source (Martínez-Sánchez 2022, PMID 34042282)
38263682 2024 Global retinoblastoma studies: A review. Topic-resolved source (Vempuluru 2024, PMID 38263682)
1800925 1991 Diffuse infiltrating retinoblastoma. Topic-resolved source (Bhatnagar 1991, PMID 1800925)
34226484 2021 Retinoblastoma: A Major Review. Topic-resolved source (Roy 2021, PMID 34226484)
17543516 2007 Retinoblastoma epidemiology: does the evidence matter? Topic-resolved source (Mastrangelo 2007, PMID 17543516)
24729462 2014 A population-based study of retinoblastoma incidence and survival in Argentine children. Topic-resolved source (Moreno 2014, PMID 24729462)
38615905 2024 Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Topic-resolved source (Zhou 2024, PMID 38615905)
31195906 2019 Retinoblastoma in Low- and Middle-Income Countries. Topic-resolved source (Chintagumpala 2019, PMID 31195906)
26023180 2016 Retinoblastoma. Topic-resolved source (Ortiz 2016, PMID 26023180)
22414599 2012 Retinoblastoma. Topic-resolved source (Dimaras 2012, PMID 22414599)
36727311 2023 Intraarterial chemotherapy for retinoblastoma in low and lower-middle-income countries - Can we break the barriers? Topic-resolved source (Honavar 2023, PMID 36727311)
35820112 2022 Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Topic-resolved source (Dunkel 2022, PMID 35820112)
30385881 2019 Retinoblastoma in Asia. Topic-resolved source (Jain 2019, PMID 30385881)
36756097 2022 Retinoblastoma: Poster-Child Tumor of the Low-Middle Income Countries (LMICs)!!! Topic-resolved source (Ramanathan 2022, PMID 36756097)
8199450 1993 Retinoblastoma. Topic-resolved source (Abramson 1993, PMID 8199450)
1331956 1992 [Retinoblastoma]. Topic-resolved source (Bouffet 1992, PMID 1331956)
35093203 2022 Retinoblastoma outcomes: a global perspective. Topic-resolved source (Finger 2022, PMID 35093203)

Source chronology

Era marker PMID What the record contributes
1979 372907 Retinoblastoma. (Bishop 1979, PMID 372907)
1991 1800925 Diffuse infiltrating retinoblastoma. (Bhatnagar 1991, PMID 1800925)
1992 1331956 [Retinoblastoma]. (Bouffet 1992, PMID 1331956)
1993 8199450 Retinoblastoma. (Abramson 1993, PMID 8199450)
1997 9333268 Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. (Wong 1997, PMID 9333268)
2006 16934146 Retinoblastoma. (Aerts 2006, PMID 16934146)
2007 16572402 Trilateral retinoblastoma. (Antoneli 2007, PMID 16572402)
2007 17543516 Retinoblastoma epidemiology: does the evidence matter? (Mastrangelo 2007, PMID 17543516)
2011 21546735 Orbital retinoblastoma: where do we go from here? (Ali 2011, PMID 21546735)
2012 22414599 Retinoblastoma. (Dimaras 2012, PMID 22414599)
2014 24729462 A population-based study of retinoblastoma incidence and survival in Argentine children. (Moreno 2014, PMID 24729462)
2014 25473349 Retinoblastoma: An overview. (Pandey 2014, PMID 25473349)
2015 27189421 Retinoblastoma. (Dimaras 2015, PMID 27189421)
2016 26023180 Retinoblastoma. (Ortiz 2016, PMID 26023180)
2016 26679524 [Retinoblastoma update]. (Aerts 2016, PMID 26679524)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • How much of mortality is mediated by parent, referral, treatment-start and abandonment intervals? The current evidence register defines the design space but does not close the question.

  • What are age-standardised incidence trends in under-covered registries? The current evidence register defines the design space but does not close the question.

  • Which awareness interventions change stage rather than knowledge alone? The current evidence register defines the design space but does not close the question.

References

  1. Dimaras H, et al. Retinoblastoma. Nature reviews. Disease primers. 2015;1:15021. PMID 27189421
  2. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  3. Das S, et al. Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Indian journal of ophthalmology. 2025;73:1124-1131. PMID 40719713
  4. Pant G, et al. Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. Pediatric hematology and oncology. 2017;34:419-424. PMID 29337595
  5. Byroju VV, et al. Retinoblastoma: present scenario and future challenges. Cell communication and signaling : CCS. 2023;21:226. PMID 37667345
  6. Bishop JO. Retinoblastoma. Pediatric annals. 1979;8:12-33. PMID 372907
  7. Aerts I, et al. Retinoblastoma. Orphanet journal of rare diseases. 2006;1:31. PMID 16934146
  8. Antoneli CB, et al. Trilateral retinoblastoma. Pediatric blood & cancer. 2007;48:306-10. PMID 16572402
  9. Wong FL, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262-7. PMID 9333268
  10. Damodharan S, et al. Increased Incidence of Retinoblastoma in Wisconsin: Coincidence or Public Health Concern? WMJ : official publication of the State Medical Society of Wisconsin. 2024;123:76-77. PMID 38718232
  11. Fabian ID, et al. Understanding retinoblastoma: epidemiology and genetics. Community eye health. 2018;31:7. PMID 29915458
  12. Cruz-Gálvez CC, et al. Retinoblastoma: Review and new insights. Frontiers in oncology. 2022;12:963780. PMID 36408154
  13. AlAli A, et al. Retinoblastoma for Pediatric Ophthalmologists. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2018;7:160-168. PMID 29737052
  14. Pandey AN. Retinoblastoma: An overview. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. 2014;28:310-5. PMID 25473349
  15. Patel S, et al. Rare tumors: Retinoblastoma, nasopharyngeal cancer, and adrenocorticoid tumors. Pediatric blood & cancer. 2021;68 Suppl 2:e28253. PMID 33818883
  16. Ali MJ, et al. Orbital retinoblastoma: where do we go from here? Journal of cancer research and therapeutics. 2011;7:11-4. PMID 21546735
  17. Virgili G, et al. Survival and Health Care Burden of Children With Retinoblastoma in Europe. JAMA ophthalmology. 2024;142:1062-70. PMID 39388193
  18. Barbosa AC, et al. Incidence of retinoblastoma in children and adolescents in Brazil: A population-based study. Frontiers in pediatrics. 2022;10:1048792. PMID 36507141
  19. Singh L, et al. Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1147-1156. PMID 38492167
  20. Aerts I, et al. [Retinoblastoma update]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 2016;23:112-6. PMID 26679524
  21. Friedman DL, et al. Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. Pediatric blood & cancer. 2017;64. PMID 28019092
  22. Chévez-Barrios P, et al. Incidence and Survival Rates in European Children With Retinoblastoma. JAMA ophthalmology. 2024. PMID 39388174
  23. Sherief ST, et al. Incidence and geographic distribution of retinoblastoma in Ethiopia. BMC ophthalmology. 2023;23:231. PMID 37221479
  24. Martínez-Sánchez M, et al. Retinoblastoma: from discovery to clinical management. The FEBS journal. 2022;289:4371-4382. PMID 34042282
  25. Vempuluru VS, et al. Global retinoblastoma studies: A review. Clinical & experimental ophthalmology. 2024;52:334-354. PMID 38263682
  26. Bhatnagar R, et al. Diffuse infiltrating retinoblastoma. Ophthalmology. 1991;98:1657-61. PMID 1800925
  27. Roy SR, et al. Retinoblastoma: A Major Review. Mymensingh medical journal : MMJ. 2021;30:881-895. PMID 34226484
  28. Mastrangelo D, et al. Retinoblastoma epidemiology: does the evidence matter? European journal of cancer (Oxford, England : 1990). 2007;43:1596-603. PMID 17543516
  29. Moreno F, et al. A population-based study of retinoblastoma incidence and survival in Argentine children. Pediatric blood & cancer. 2014;61:1610-5. PMID 24729462
  30. Zhou M, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100058. PMID 38615905
  31. Chintagumpala M. Retinoblastoma in Low- and Middle-Income Countries. Pediatric hematology and oncology. 2019;36:53-54. PMID 31195906
  32. Ortiz MV, et al. Retinoblastoma. Journal of child neurology. 2016;31:227-36. PMID 26023180
  33. Dimaras H, et al. Retinoblastoma. Lancet (London, England). 2012;379:1436-46. PMID 22414599
  34. Honavar SG. Intraarterial chemotherapy for retinoblastoma in low and lower-middle-income countries - Can we break the barriers? Indian journal of ophthalmology. 2023;71:325-326. PMID 36727311
  35. Dunkel IJ, et al. Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40:3839-3847. PMID 35820112
  36. Jain M, et al. Retinoblastoma in Asia. Eye (London, England). 2019;33:87-96. PMID 30385881
  37. Ramanathan S, et al. Retinoblastoma: Poster-Child Tumor of the Low-Middle Income Countries (LMICs)!!! South Asian journal of cancer. 2022;11:279-280. PMID 36756097
  38. Abramson DH, et al. Retinoblastoma. Optometry clinics : the official publication of the Prentice Society. 1993;3:49-61. PMID 8199450
  39. Bouffet E, et al. [Retinoblastoma]. Pediatrie. 1992;47:399-408. PMID 1331956
  40. Finger PT, et al. Retinoblastoma outcomes: a global perspective. The Lancet. Global health. 2022;10:e307-e308. PMID 35093203